RDNT — RadNet, Inc.

Is RDNT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of November 17, 2026

RadNet, Inc. (RDNT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $76.89. The rating moved from Neutral to Overbought on November 17, 2026.

See all overbought Healthcare stocks →

AI analysis

RadNet, Inc. (RDNT) operates a large outpatient diagnostic imaging platform with steady underlying demand and growth driven by acquisitions and site expansion. Core upside drivers include integration of recent deals, margin improvement from workflow automation and AI, and stabilization of payer mix; downside is concentrated on reimbursement/regulatory pressure from Medicare Advantage actions, acquisition execution, and volume sensitivity to macro conditions. Near-term sentiment is muted amid defensive flows, but the company’s future trajectory will track utilization trends, pricing environment, and progress on leverage reduction. Investors should watch upcoming payer announcements, utilization data, and quarterly cash flow execution for directional signals.

Key factors

  • Large outpatient imaging footprint with recurring diagnostic demand provides revenue stability versus elective-only exposures
  • Growth strategy driven by tuck-in acquisitions and ambulatory expansion that can increase market share and organic utilization
  • Operational leverage potential from IT/AI workflow improvements and site-of-care optimization that can lift margins over time
  • Significant Medicare/Medicare Advantage payer exposure; reimbursement trends materially affect near-term cash flow
  • Balance between steady demand for imaging and sensitivity to elective care cycles makes performance tied to utilization trends
  • Market risk-off environment and defensive sector flows may limit near-term valuation upside despite operational progress

Risks

  • CMS regulatory tightening (RADV/anti-billing measures) and Medicare Advantage scrutiny that could increase clawbacks or lower realized reimbursement
  • Downward pressure on imaging reimbursement and pricing from payors or policy changes
  • Acquisition integration risks, including achieving expected synergies and managing incremental leverage
  • Volume sensitivity to macro weakness or reduced elective procedures, especially in risk-off market conditions
  • Competition from hospital-owned imaging, specialty providers, and in-office imaging reducing pricing power
  • Execution risk on cost initiatives and IT/AI rollouts; delayed efficiency gains would compress margins

See today's live rating, score and targets

Members see the live hourly rating for RDNT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.